Signal transduction by protein tyrosine kinases and antitumor agents

Yaoxue Xuebao

Volumn 43, Issue 4, 2008, Pages 323-334

  Mao, Yong Jun ^a   Li, Hai Hong ^b   Li, Jian Feng ^a   Shen, Jing Shan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b Topharman Shanghai Co Ltd   (China)

Author keywords

Antitumor agent; Non receptor protein tyrosine kinase; Protein tyrosine kinases inhibitor; Receptor protein tyrosine kinase; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; STAT PROTEIN;

ANIMAL; DRUG EFFECT; HUMAN; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN-TYROSINE KINASES; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT TRANSCRIPTION FACTORS;

EID: 44649097556     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Tang ZY. Modern Oncology [M]. 2nd ed. Shanghai: Fudan University Press, 2003:202-223.
2. Huang WL, Zhu XF. Signal Transduction [M]. Beijing: People's Medical Publishing House, 2005:151-199.
3. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules [J]. Nature, 2006, 441:457-462.
4. Zhu XF, Liu ZC, Zeng YX. Tyrosine kinase receptor-mediated signal transduction and cancer treatment [J]. Acta Pharm Sin, 2002, 37:229-234.
5. Deng XQ, Xiang ML, Jia R, et al. Progress in the design of selective ATP-competitive kinase inhibitors [J]. Acta Pharm Sin, 2007, 42:1232-1236.
6. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity [J]. Cell Signal, 2001, 13:777-785.
7. Shaw RJ, Cantley LC. Ras, PI (3) K and mTOR signaling controls tumour cell growth [J]. Nature, 2006, 441:424-430.
8. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage [J]. Clin Cancer Res, 2006, 12:1398-1401.
9. Schenone S. Manetti F. Botta M. Src inhibitors and angiogenesis [J]. Curr Pharm Design, 2007, 13:2118-2128.
10. Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia [J]. Nat Rev Cancer, 2007, 7:345-356.
11. Murray PJ. The JAK-STAT signaling pathway: input and output integration [J]. J Immunol, 2007, 178:2623-2629.
12. Pharmaprojects V5 [DB/0L]. http://203.156.214.150/citrix/nfuse17/ frameset.asp. 2007-12-30.
13. Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development [J]. Med Res Rev, 2006, 26:569-594.
14. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy [J]. Clin Cancer Res, 2006, 12:5268-5272.
15. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy [J]. Clin Cancer Res, 2004, 10:784-793.
16. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer [J]. Cancer Res, 2005, 65:4389-4400.
17. Reid A, Vidal L, Shaw H, et al. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu) [J]. Eur J Cancer, 2007, 43:481-489.
18. Naumova E, Ubezio P, Garofalo A, et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis [J]. Clin Cancer Res, 2006, 12:1839-1849.
19. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis [J]. Eur Respir J, 2007, 29:976-985.
20. Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK222584 administered twice daily in patients with advanced cancer [J]. J Clin Oncol, 2005, 23:4162-4171.
21. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts [J]. Am J Pathol, 2004, 165:35-52.
22. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG706, an oral multikinase inhibitor, in patients with advanced solid tumors [J]. J Clin Oncol, 2007, 25:2369-2376.
23. Wong KK, HKI-272 in non-small cell lung cancer [J]. Clin Cancer Res, 2007, 13:4593-4596.
24. Younes MN, Yazici YD, Kim S, et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer [J]. Clin Cancer Res, 2006, 12:3425-3434.
25. Harousseau JL. Farnesyltransferase inhibitors in hematologic malignancies [J]. Blood Rev, 2007, 21:173-182.
26. Reuter CW, Morgan MA, Grünwald V, et al. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma [J]. World J Urol, 2007, 25:59-72.
27. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy [J]. Ann Med, 2006, 38:200-211.
28. Ma FY, Flanc RS, Tesch GH, et al. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis [J]. J Am Soc Nephrol, 2007, 18:472-484.
29. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer [J]. Nat Rev Cancer, 2002, 2:489-501.
30. Drugs moving into the clinic [EB/OL]. 2007:1-39. http://www. drugresearcher.com. 2007-12-20.
31. de la Pena L, Burgan WE, Carter DJ, et al. Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells [J]. Mol Cancer Ther, 2006, 5:1504-1510.
32. MacKenzie AR, von Mehren M. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future [J]. Expert Rev Anticancer Ther, 2007, 7:1145-1154.
33. Martelli AM, Tazzari PL, Evangelisti C, et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside [J]. Curr Med Chem, 2007, 14:2009-2023.
34. Zheng HY, Hu JD, Zheng ZH, et al. Emodin induces leukemic HL-60 cells apoptosis probably by inhibiting Akt signal pathway [J]. Acta Pharm Sin, 2007, 42:1142-1146.
35. Boschelli DH, Wu B, Ye F, et al. Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl) amino]-7-furyl-3- quinolinecarbonitriles [J]. J Med Chem, 2006, 49:7868-7876.
36. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by Bcr-Abl gene mutation or amplification [J]. Science, 2001, 293:876-880.
37. Schenone S, Manetti F, Botta M. Last findings on dual inhibitors of Abl and Src tyrosine-kinases [J]. Mini Rev Med Chem, 2007, 7: 191-201.
38. von Mehren M. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors [J]. Clin Colorectal Cancer, 2006, 6: 30-34.
39. Jabbour E, Cortes JE, Giles FJ, et al. Current and emerging treatment options in chronic myeloid leukemia [J]. Cancer, 2007, 109: 2171-2181.
40. O'Sullivan LA, Liongue C, Lewis RS, et al. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease [J]. Mol Immunol, 2007, 44: 2497-2506.
41. Kumar S, Raje N, Hideshima T, et al. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs [J]. Leukemia, 2005, 19:1253-1261.
42. Barton BE, Karras JG, Murphy TF, et al. Signal transducer and activator of transcription3 (STAT3) activation in prostate cancer; direct STAT3 inhibition induces apoptosis in prostate cancer lines [J]. Mol Cancer Ther, 2004, 3: 11-20.
43. Blaskovich MA, Sun J, Cantor A, et al. Discovery of JSI-124 (Cucurbitacin I), a selective Janus kinase/ signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice [J]. Cancer Res, 2003, 63:1270-1279.
44. Schenone S, Bondavalli F, Botta M. Antiangiogenic agents; an update on small molecule VEGFR inhibitors [J]. Curr Med Chem, 2007, 14:2495-2516.
45. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers [J]. J Clin Oncol, 2007, 25:4033-4042.